⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLNO News
Soleno Therapeutics, Inc. Common Stock
INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit filed by Robbins Geller Rudman & Dowd LLP
businesswire.com
SLNO
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
SLNO
INVESTOR ALERT: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
prnewswire.com
SLNO
Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit
businesswire.com
SLNO
Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Soleno Therapeutics, Inc., Announces Opportunity for Investors with Substantial Losses to Lead Soleno Class Action Lawsuit
globenewswire.com
SLNO
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
globenewswire.com
SLNO
Form 8-K
sec.gov
SLNO
Form 8-K
sec.gov
SLNO
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT⢠XR
globenewswire.com
SLNO
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
globenewswire.com
SLNO